Premium
Pancreatic cancer genomics: where can the science take us?
Author(s) -
Graham J.S.,
Jamieson N.B.,
Rulach R.,
Grimmond S.M.,
Chang D.K.,
Biankin A.V.
Publication year - 2015
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1111/cge.12536
Subject(s) - pancreatic ductal adenocarcinoma , pancreatic cancer , medicine , incidence (geometry) , clinical trial , disease , intensive care medicine , randomized controlled trial , cancer , general surgery , physics , optics
The incidence of pancreatic ductal adenocarcinoma ( PDAC ) is steadily increasing and the annual death‐to‐incidence ratio approaches one. This is a figure that has not changed for several decades. Surgery remains the only chance of cure; however, only less than 20% of patients are amenable to operative resection. Despite successful surgical resection, the majority of the patients still succumb to recurrent metastatic disease. Therefore, there is an urgent need to develop novel therapeutic strategies and to better select patients for current therapies. In this review, we will discuss current management by highlighting the landmark clinical trials that have shaped current care. We will then discuss the challenges of therapeutic development using the current randomized‐controlled trial paradigm when confronted with the molecular heterogeneity of PDAC . Finally, we will discuss strategies that may help to shape the management of PDAC in the near future.